Sildenafil is a prescription phosphodiesterase type 5 inhibitor used in FDA-approved products for erectile dysfunction. Its effectiveness in ED was established in randomized placebo-controlled clinical trials evaluating the ability to achieve and maintain erections sufficient for satisfactory sexual activity.
The medicine works by enhancing an existing nitric oxide–cGMP signaling pathway during sexual stimulation rather than independently initiating an erection. Current labeling states that sildenafil at recommended doses has no effect in the absence of sexual stimulation.
This page brings together the indication, clinical evidence, mechanism, general label-based timing framework and major safety issues. It does not select an individual dose or determine whether sildenafil is appropriate for a particular person; those decisions depend on the specific product labeling and clinical context.
Sildenafil is a PDE5 inhibitor indicated in specific U.S. products for the treatment of erectile dysfunction. In this context, the therapeutic goal evaluated in clinical studies was improved ability to achieve and maintain an erection sufficient for satisfactory sexual activity.
Clinical evidence extends beyond a mechanism-based rationale. Sildenafil tablets were evaluated primarily at 25 mg, 50 mg and 100 mg in 21 randomized, double-blind, placebo-controlled studies lasting up to 6 months and involving more than 3,000 patients aged 19 to 87 years.
Those studies included ED of organic, psychogenic and mixed etiologies and consistently showed statistically significant improvement over placebo. This ED use remains distinct from sildenafil products whose approved indication is pulmonary arterial hypertension.
| Feature | Erectile Dysfunction Context |
|---|---|
| Active ingredient | Sildenafil |
| Drug class | PDE5 inhibitor |
| FDA-approved use | Treatment of erectile dysfunction in applicable sildenafil products |
| Controlled-trial evidence | 21 randomized double-blind placebo-controlled studies; more than 3,000 patients |
| Other sildenafil indications | Separate product and label contexts exist for pulmonary arterial hypertension |
An indication is an approved clinical use attached to a specific drug product and its labeling. Current U.S. sildenafil tablet and oral-film labeling includes erectile dysfunction as an approved indication.
Conventional ED sildenafil tablets are commonly supplied in 25 mg, 50 mg and 100 mg strengths. VYBRIQUE, a sildenafil oral film approved for ED, is available in 25 mg, 50 mg, 75 mg and 100 mg strengths. These dosage-form differences do not change the need to interpret use through the applicable product label.
Sildenafil is also the active drug in PAH-oriented products, but sharing an active ingredient does not merge the ED and PAH regulatory frameworks. For the broader indication map, see the sildenafil uses page.
| Product Context | Approved-Use Framework |
|---|---|
| Conventional sildenafil / Viagra-type tablets | Erectile dysfunction |
| VYBRIQUE oral film | Erectile dysfunction |
| Revatio / PAH-oriented sildenafil products | Pulmonary arterial hypertension |
| Active ingredient | Sildenafil can appear across these different product contexts |
During sexual stimulation, nitric oxide is released locally and activates guanylate cyclase, increasing cyclic guanosine monophosphate, or cGMP. Increased cGMP contributes to smooth-muscle relaxation and blood inflow involved in the erectile response.
PDE5 normally degrades cGMP. Sildenafil inhibits PDE5, slowing that degradation and thereby enhancing the effect of the nitric oxide signal that has already been generated.
Sildenafil therefore amplifies a physiological signaling pathway rather than acting as a direct mechanical or independent erectile stimulus. For a lower-jargon explanation, see how sildenafil works.
| Mechanism Component | Role |
|---|---|
| Sexual stimulation | Triggers local nitric oxide release |
| Nitric oxide | Activates guanylate cyclase |
| cGMP | Supports smooth-muscle relaxation and blood inflow |
| PDE5 | Breaks down cGMP |
| Sildenafil | Inhibits PDE5 and enhances existing NO–cGMP signaling |
Sildenafil does not directly release nitric oxide, manufacture cGMP or produce an erection independently of physiological stimulation. Its pharmacological role begins downstream from nitric oxide release.
Current prescribing information specifically states that sildenafil at recommended doses has no effect in the absence of sexual stimulation. That point is fundamental to understanding what PDE5 inhibition can and cannot do.
The mechanism is therefore better described as enhancement of an existing erectile-response pathway rather than an automatic switch. More detailed signaling biology is covered in the dedicated PDE5 and NO–cGMP research pages.
| Statement | Correct? |
|---|---|
| Sildenafil inhibits PDE5 | Yes |
| Sexual stimulation provides the upstream NO signal | Yes |
| Sildenafil directly creates nitric oxide | No |
| Sildenafil directly produces cGMP | No |
| Sildenafil works independently of sexual stimulation | No |
The current ED label provides an administration window rather than promising one exact onset time for every patient. For most patients, conventional sildenafil labeling describes use approximately 1 hour before sexual activity, while allowing administration from 30 minutes to 4 hours beforehand.
That timing framework should not be confused with Tmax. Under fasting conditions sildenafil generally reaches peak plasma concentration within approximately 30 to 120 minutes, but pharmacodynamic response can begin before the plasma peak.
Onset varies because absorption and pharmacodynamic response vary between individuals and conditions. The more detailed evidence and the distinction between administration timing, Tmax and observed response remain on the sildenafil onset page.
| Timing Concept | ED Context |
|---|---|
| Typical label timing | Approximately 1 hour before sexual activity |
| Label administration window | 30 minutes to 4 hours before sexual activity |
| Tmax | Peak plasma concentration generally occurs within 30–120 minutes fasting |
| Onset | Beginning of observed pharmacodynamic response; not identical to Tmax |
Sildenafil duration is better understood as a window of enhanced erectile responsiveness rather than a continuous erection. Current labeling reports that erectile response was demonstrated for up to 4 hours after administration.
The response at 4 hours was diminished compared with the response measured at 2 hours, showing that the pharmacodynamic effect declines gradually rather than ending at a precise cutoff.
Sildenafil's terminal plasma half-life is also approximately 4 hours, but that numerical similarity does not make half-life and clinical duration equivalent concepts. The complete interpretation is covered on the sildenafil duration page.
| Concept | What It Describes |
|---|---|
| Label-based response window | Effect demonstrated for up to 4 hours |
| Response at 4 hours | Diminished compared with the 2-hour response |
| Terminal half-life | Approximately 4-hour concentration-decline timescale |
| Continuous erection | Not what the several-hour effect window means |
Food can alter the early pharmacokinetic profile of oral sildenafil, particularly after a high-fat meal. For conventional tablets, current labeling reports a mean delay in Tmax of approximately 60 minutes and a mean Cmax reduction of approximately 29%.
Those changes indicate slower development of peak systemic exposure. They do not establish that effectiveness or duration falls by the same percentage.
Food effects also vary by dosage form; newer sildenafil oral-film labeling has a different quantitative fed-state profile. Detailed formulation-specific evidence remains on the sildenafil food effects page.
| Food-Related Measure | Conventional Tablet High-Fat Meal Effect |
|---|---|
| Absorption rate | Slower |
| Tmax | Mean delay approximately 60 minutes |
| Cmax | Mean reduction approximately 29% |
| Clinical response | Cannot be calculated directly from these PK percentages |
Not every patient experiences the same response to sildenafil. Controlled trials show a clear average treatment effect compared with placebo, but they also demonstrate that response is probabilistic rather than guaranteed.
In four fixed-dose randomized studies involving 1,797 patients, 63% of patients receiving 25 mg, 74% receiving 50 mg and 82% receiving 100 mg reported improvement in erections, compared with 24% receiving placebo. These percentages describe trial populations and should not be used to predict one person's result.
Underlying ED cause, baseline severity, systemic drug exposure and pharmacodynamic differences can all influence treatment response. Broader pharmacokinetic variability is discussed on the sildenafil PK variability page.
| Fixed-Dose Trial Group | Patients Reporting Improved Erections |
|---|---|
| Placebo | 24% |
| Sildenafil 25 mg | 63% |
| Sildenafil 50 mg | 74% |
| Sildenafil 100 mg | 82% |
Sildenafil adverse effects reflect both its intended PDE5 pharmacology and activity in other physiological systems. Current U.S. labeling identifies headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash among the most common adverse reactions reported in clinical trials at rates of at least 2%.
In flexible-dose placebo-controlled studies, headache was reported in approximately 16% of sildenafil-treated patients versus 4% with placebo, flushing in 10% versus 1%, dyspepsia in 7% versus 2%, nasal congestion in 4% versus 2% and abnormal vision in 3% versus 0%.
These are population-level trial frequencies rather than predictions for an individual patient. Serious but less common safety issues are handled separately under warnings and precautions. The dedicated sildenafil side effects page provides the full adverse-reaction context.
| Adverse Reaction | Flexible-Dose Sildenafil | Placebo |
|---|---|---|
| Headache | 16% | 4% |
| Flushing | 10% | 1% |
| Dyspepsia | 7% | 2% |
| Nasal congestion | 4% | 2% |
| Abnormal vision | 3% | 0% |
| Dizziness | 2% | 1% |
Current U.S. ED-oriented sildenafil labeling contains three core formal contraindication categories: use with nitric oxide donors such as organic nitrates or nitrites, use with guanylate cyclase stimulators such as riociguat, and known hypersensitivity to sildenafil or the relevant product components.
These formal contraindications should be distinguished from warnings and other drug interactions. For example, alpha-blockers and antihypertensive medicines can increase the risk of hypotension but are not classified as the same universal contraindication as nitrates.
The complete distinction among formal contraindications, precautions and interactions is covered on the sildenafil contraindications page.
| Contraindication Category | Current U.S. Label Context |
|---|---|
| Nitric oxide donors | Organic nitrates or organic nitrites are contraindicated |
| Guanylate cyclase stimulators | Riociguat and related GC stimulators are contraindicated |
| Known hypersensitivity | Contraindicated when hypersensitivity to sildenafil or applicable product components is known |
Nitrates are a formal contraindication with sildenafil rather than a minor interaction. Sildenafil potentiates the hypotensive effects of nitric oxide donors, including organic nitrates and organic nitrites.
The pharmacological overlap occurs because nitrates increase nitric oxide–cGMP signaling while sildenafil slows PDE5-mediated cGMP breakdown. Combining the two can produce excessive vasodilation and clinically important blood-pressure reduction.
Current labeling does not establish a universally safe time after sildenafil at which nitrate administration can be assumed safe. The full mechanism and regulatory context are covered on the sildenafil and nitrates page.
| Interaction Feature | Context |
|---|---|
| Sildenafil | PDE5 inhibition slows cGMP degradation |
| Nitrates | Increase nitric oxide–cGMP signaling |
| Combined effect | Potentially excessive blood-pressure lowering |
| Label classification | Contraindicated |
Riociguat is a soluble guanylate cyclase stimulator, and current U.S. sildenafil labeling contraindicates concomitant use with this drug class.
Both therapies increase activity within the cGMP-related vascular pathway through different mechanisms. Sildenafil reduces cGMP degradation, while riociguat stimulates soluble guanylate cyclase, creating a risk of additive hypotensive effects.
This is therefore a formal contraindication rather than merely a theoretical pathway overlap. The dedicated sildenafil and riociguat page covers the interaction in greater depth.
| Topic | Interpretation |
|---|---|
| Sildenafil | PDE5 inhibitor |
| Riociguat | Soluble guanylate cyclase stimulator |
| Combined pathway | Can potentiate hypotensive effects |
| Label classification | Contraindicated |
Not all clinically important sildenafil interactions are contraindications. Some alter systemic exposure through CYP3A4 metabolism, while others produce additive effects on blood pressure.
Current labeling notes that CYP3A4 inhibitors such as ritonavir, ketoconazole, itraconazole and erythromycin can increase sildenafil exposure. Alpha-blockers and antihypertensive medicines can also contribute to additional blood-pressure lowering.
Interaction magnitude and label management are drug-specific, so these examples should not be reduced to one universal rule. The broader mechanism and evidence map is available on the sildenafil drug interactions page.
| Interaction Category | General Sildenafil Effect |
|---|---|
| Nitrates / GC stimulators | Contraindicated pharmacodynamic interactions |
| Alpha-blockers / antihypertensives | Potential additive hypotension |
| CYP3A4 inhibitors | Can increase sildenafil systemic exposure |
| Other PDE5 inhibitors / ED therapies | Combination not recommended in current ED-oriented labeling |
Current sildenafil safety labeling contains clinically important warnings beyond formal drug interactions. Sexual activity itself can pose cardiovascular strain, and labeling states that sildenafil should not be used when sexual activity is inadvisable because of cardiovascular status.
Other warnings include prolonged erection or priapism, sudden vision loss that may represent non-arteritic anterior ischemic optic neuropathy, sudden decrease or loss of hearing and hypotension when sildenafil is combined with alpha-blockers or antihypertensive medicines.
An erection lasting more than 4 hours requires emergency medical attention, and sudden vision or hearing changes require prompt medical evaluation. These warning categories are covered in greater detail on the sildenafil warnings page.
| Warning Area | General Label Context |
|---|---|
| Cardiovascular status | Sildenafil should not be used when sexual activity is inadvisable because of cardiovascular status |
| Prolonged erection / priapism | Emergency attention if an erection lasts more than 4 hours |
| Sudden vision loss | Stop use and seek medical care |
| Sudden hearing decrease or loss | Stop use and seek prompt medical attention |
| Hypotension | Caution with alpha-blockers and antihypertensive medicines |
Erectile dysfunction is one major approved sildenafil use, but it is not the only U.S. regulatory context for the active drug. Sildenafil is also used in products approved for pulmonary arterial hypertension.
The active moiety and PDE5 pharmacology are shared, while indications, product strengths, formulations, dosage regimens and application histories differ. Conventional ED sildenafil tablets and newer sildenafil oral film belong to the ED framework, while products such as Revatio and LIQREV belong to PAH-oriented labeling.
These distinctions matter because a strength or brand name does not by itself define how sildenafil should be interpreted clinically. The broader indication map is covered on sildenafil uses, while the PAH context is covered on sildenafil for pulmonary hypertension.
| Context | Examples | Regulatory Relationship |
|---|---|---|
| Erectile dysfunction | Sildenafil / Viagra-type tablets; VYBRIQUE oral film | ED-specific labeling |
| Pulmonary arterial hypertension | Revatio; LIQREV and related sildenafil products | Separate PAH labeling |
| Active drug | Sildenafil | Shared across product contexts |
| Dosage and administration | Product-specific | Should not be transferred automatically between ED and PAH products |
A complete indication overview needs enough label-based context to explain how sildenafil is used without becoming a personalized dose-selection guide. Current ED labeling states that for most patients the recommended dose is 50 mg taken as needed approximately 1 hour before sexual activity, with a permitted administration window of 30 minutes to 4 hours.
Labeling also permits adjustment within the 25 mg to 100 mg framework based on effectiveness and tolerability and sets a maximum recommended dosing frequency of once per day. Those numbers describe the approved general framework rather than an instruction for an individual reader.
Age, organ function, interacting medicines and other clinical factors can change the applicable label recommendations. Detailed dose and adjustment information therefore remains on the sildenafil dosage page.
| General Label Information | ED Context |
|---|---|
| Usual labeled dose for most patients | 50 mg as needed |
| Typical timing | Approximately 1 hour before sexual activity |
| Permitted timing window | 30 minutes to 4 hours beforehand |
| Label range | 25 mg to 100 mg depending on effectiveness and tolerability |
| Maximum recommended frequency | Once per day |
| Individual dose selection | Requires product-specific labeling and clinical assessment |
Sildenafil for erectile dysfunction is supported by both a defined pharmacological mechanism and controlled clinical evidence. It enhances an existing nitric oxide–cGMP pathway through PDE5 inhibition, and placebo-controlled trials demonstrated improved erectile function across patients with multiple ED etiologies.
The benefit is not automatic or universal. Sildenafil requires sexual stimulation for its labeled erectile-response mechanism, treatment response varies between patients and safety depends on contraindications, cardiovascular context, interacting medicines and other individual factors.
The most useful framework therefore combines five questions: is the product actually labeled for ED, what clinical evidence supports benefit, how does PDE5 inhibition work, what timing framework applies and what safety restrictions need to be considered.
| Question | Sildenafil ED Answer |
|---|---|
| Is sildenafil FDA-approved for ED? | Yes, in applicable sildenafil products |
| Is effectiveness supported by controlled trials? | Yes; sildenafil improved erectile-function outcomes versus placebo in 21 randomized controlled studies |
| How does it act? | Enhances NO–cGMP signaling through PDE5 inhibition |
| Does it work without sexual stimulation? | No effect is expected at recommended doses in the absence of sexual stimulation |
| What is the general timing framework? | Typically about 1 hour beforehand, with a labeled 30-minute to 4-hour administration window |
| How long can response remain detectable? | Up to about 4 hours in labeling studies, with diminished response at the later time point |
| What are the core formal contraindications? | Nitrates or nitrites, GC stimulators such as riociguat, and known hypersensitivity |
Yes. Sildenafil is a PDE5 inhibitor indicated for erectile dysfunction in applicable U.S. products, including conventional sildenafil tablets and sildenafil oral-film products.
Sildenafil was evaluated in 21 randomized, double-blind, placebo-controlled trials involving more than 3,000 patients. In four fixed-dose studies, 63%, 74% and 82% of patients receiving 25 mg, 50 mg and 100 mg reported improved erections, respectively, compared with 24% receiving placebo.
During sexual stimulation, nitric oxide increases cGMP signaling involved in smooth-muscle relaxation and blood inflow. Sildenafil inhibits PDE5, which normally breaks down cGMP, thereby enhancing that existing physiological signal.
No. Current labeling states that sildenafil at recommended doses has no effect in the absence of sexual stimulation.
For most patients, current conventional ED labeling describes sildenafil approximately 1 hour before sexual activity, with a permitted window from 30 minutes to 4 hours beforehand. This is general label information rather than individualized dosing advice.
Current U.S. labeling contraindicates sildenafil with nitric oxide donors such as organic nitrates or nitrites, with guanylate cyclase stimulators such as riociguat, and in people with known hypersensitivity to sildenafil or applicable product components.